Abstract
BackgroundRituximab is a chimeric anti-CD20 antibody approved in a few indications apart from oncology (rheumatoid arthritis, polyangiitis and Wegener’s granulomatosis). The French funding system allows the off-label use of rituximab...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
